Viral Shah, MD, an endocrinologist and scientist, discusses the growing field of research into the connections between type 1 diabetes (T1D) and osteoporosis.
There are gender differences in bone fracture risk, osteoposoris, and type 1 diabetes that are still being explored, according to Viral Shah, MD, an endocrinologist and associate professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, Adult Clinic School of Medicine at the University of Colorado Anschutz campus.
Transcript
What is the relationship between type 1 diabetes and osteoporosis and bone fractures?
That's a great question. I have been involved in research of type 1 diabetes and osteoporosis for now, a couple of years, and it's very interesting. Little is known about how type 1 diabetes influences the bone. First, we looked around the literature and tried to see what's the fracture risk in people with type 1 diabetes, and it's very surprising.
We found out that, particularly females, postmenopausal females with type 1 diabetes have a 6-fold higher risk for fractures than females without diabetes. And not only that, men with type 1 diabetes also have a higher fracture risk than females without diabetes. So with that research, it was a very surprising finding that the fracture risk was very high in people with type 1 diabetes. And that made us do more research about why people with type 1 diabetes are having a higher fracture risk.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
2 Commerce Drive
Cranbury, NJ 08512